natgillin/translations-raw huggingface dataset:
Lipid disorders should be managed as clinically appropriate (see section 4.8).
Lipidne motnje moramo primerno klinično obravnavati (glejte poglavje 4. 8).
Pancreatitis: pancreatitis has been reported, but a causal relationship to Ziagen treatment is uncertain.
Poročajo o primerih pankreatitisa, vendar vzročna povezava z zdravljenjem z zdravilom Ziagen ni dokazana.
Triple nucleoside therapy: in patients with high viral load (> 100,000 copies/ ml) the choice of a triple combination with abacavir, lamivudine and zidovudine needs special consideration (see section 5.1).
Pri bolnikih z visoko virusno obremenitvijo (> 100. 000 kopij/ ml) je treba tehtno razmisliti o odločitvi za trojno kombinacijo z abakavirjem, lamivudinom in zidovudinom (glejte poglavje 5. 1).
Once daily administration (abacavir 600 mg): the benefit of abacavir as a once daily regimen is mainly based on a study performed in combination with efavirenz and lamivudine, in antiretroviral- naïve adult patients (see section 5.1).
(glejte poglavje 5. 1).
Liver disease: the safety and efficacy of Ziagen has not been established in patients with significant underlying liver disorders.
Pri bolniki z hudimi motnjami v delovanju ledvic, varnost in učinkovitost zdravila Ziagen nista bili dokazani.
Ziagen is contraindicated in patients with severe hepatic impairment (see section 4.3).
Zdravilo Ziagen je kontraindicirano pri bolnikih s hudo jetrno okvaro.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
Bolniki s kroničnim hepatitisom B ali C, ki se hkrati zdravijo z več protiretrovirusnimi zdravili, so izpostavljeni višjemu tveganju za pojav hudih neželenih učinkov na jetrih, lahko tudi s smrtnim izidom.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
V primeru hkratnega protivirusnega zdravljenja hepatitisa B in C, si prosimo preberite tudi navodila za uporabo teh zdravil.
However, a definitive recommendation on dose reduction is not possible due to substantial variability of drug exposure in this patient population (see section 5.2).
Na bolnikih z blago jetrno okvaro so izvedli farmakokinetično študijo, vendar natančnejših napotkov za znižanje odmerka ni možno dati, ker pri tej populaciji bolnikov izpostavljenost zdravilu opazno niha (glejte poglavje 5. 2).
The clinical safety data available with abacavir in hepatically impaired patients is very limited.
Klinični podatki o varnosti abakavirja pri bolnikih z jetrno okvaro so zelo omejeni.
Due to the potential increases in exposure (AUC) in some patients, close monitoring is required.
Ker pri nekaterih bolnikih prihaja do potencialnega povečanja izpostavljenosti (AUC), je treba takšne bolnike skrbno nadzorovati.
No data are available in patients with moderate or severe hepatic impairment.
Za bolnike z zmerno ali hudo jetrno okvaro ni podatkov.
Plasma concentrations of abacavir are expected to substantially increase in these patients.
Pričakovati je, da se bodo plazemske koncentracije abakavirja pri teh bolnikih znatno povečale.
Therefore, the use of abacavir in patients with moderate hepatic impairment is not recommended unless judged necessary and requires close monitoring of these patients.
Zato uporabe abakavirja pri bolnikih z zmerno jetrno okvaro ne priporočajo, v nasprotnem primeru je treba take bolnike pazljivo spremljati.
For patients with severe hepatic impairment, Ziagen is contraindicated (see section 4.3).
Pri bolnikih s hudo jetrno okvaro je zdravilo Ziagen kontraindicirano (glejte poglavje 4. 3).
Renal disease:
Bolezen ledvic:
Ziagen should not be administered to patients with end-stage renal disease (see section 5.2).
Zdravila Ziagen ne smemo dajati bolnikom v končnem stadiju ledvične odpovedi (glejte poglavje 5. 2).
Opportunistic infections: patients receiving Ziagen or any other antiretroviral therapy may still develop opportunistic infections and other complications of HIV infection.
Pri bolnikih, ki prejemajo zdravilo Ziagen ali katerokoli drugo protiretrovirusno zdravljenje, se lahko kljub temu razvijejo oportunistične okužbe ali drugi zapleti, povezani z okužbo s HIV.
Therefore patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.
Zato morajo bolnike ves čas natančno klinično opazovati zdravniki, ki imajo izkušnje z zdravljenjem bolezni povezanih s HIV.
Transmission: patients should be advised that current antiretroviral therapy, including Ziagen, have not been proven to prevent the risk of transmission of HIV to others through sexual contact or blood contamination.
Bolnike je treba podučiti, da trenutno protiretrovirusno zdravljenje, vključno z zdravilom Ziagen, ne preprečuje tveganja prenosa virusa HIV na druge osebe s spolnim odnosom ali okuženo krvjo.
Appropriate precautions should continue to be taken.
Zato morajo še naprej upoštevati ustrezne previdnostne ukrepe.
Based on the results of in vitro experiments and the known major metabolic pathways of abacavir, the potential for P450 mediated interactions with other medicinal products involving abacavir is low.
P450 pri presnovi abakavirja
P450 does not play a major role in the metabolism of abacavir, and abacavir does not inhibit metabolism mediated by CYP 3A4.
7 ne igra pomembne vloge in abakavir ne zavira presnove na CYP3A4.
Potent enzymatic inducers such as rifampicin, phenobarbital and phenytoin may via their action on UDP-glucuronyltransferases slightly decrease the plasma concentrations of abacavir.
Močni induktorji encimov kot so rifampicin, fenobarbital in fenitoin lahko s svojim delovanjem na UDP- glukuroniltransferazo nekoliko znižajo koncentracijo abakavirja v plazmi.
Ethanol: the metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%.
Presnova abakavirja se s sočasno zaužitim etanolom spremeni, kar ima za posledico povečanje AUC abakavirja za okoli 41%.
7 Methadone: in a pharmacokinetic study, coadministration of 600 mg abacavir twice daily with methadone showed a 35% reduction in abacavir Cmax and a one hour delay in tmax but the AUC was unchanged.
V farmakokinetični študiji se je po sočasnem dajanju 600 mg abakavirja dvakrat dnevno z metadonom za 35% zmanjšal abakavirjev Cmax in za eno uro podaljšal tmax, medtem ko je AUC ostal nespremenjen.
Retinoids: retinoid compounds are eliminated via alcohol dehydrogenase.
Retinoidi se izločajo s pomočjo alkoholne dehidrogenaze.
Ziagen is not recommended during pregnancy.
Uporaba zdravila Ziagen med nosečnostjo ni priporočljiva.
The safe use of abacavir in human pregnancy has not been established.
Ni dokazano, da bi bila uporaba abakavirja med nosečnostjo pri človeku varna.
Placental transfer of abacavir and/ or its related metabolites has been shown to occur in animals.
Izkazalo se je, da pri živalih prihaja do prehoda abakavirja in/ ali njemu podobnih presnovkov skozi posteljico.
Toxicity to the developing embryo and foetus occurred in rats, but not in rabbits (see section 5.3).
Toksičnost za razvijajoč se zarodek in plod se je pojavila pri podganah, toda ne pri kuncih (glejte poglavje 5. 3).
The teratogenic potential of abacavir could not be established from studies in animals.
Iz študij na živalih niso mogli določiti teratogenega potenciala abakavirja.
Abacavir and its metabolites are secreted into the milk of lactating rats.
Abakavir in njegovi presnovki se izločajo v mleko doječih podgan.
It is expected that these will also be secreted into human milk, although this has not been confirmed.
Čeprav ni bilo potrjeno, lahko predvidevamo, da se bi izločali tudi v materino mleko.
It is therefore recommended that mothers do not breast-feed their babies while receiving treatment with abacavir.
Zato priporočamo, naj matere v času zdravljenja z abakavirjem ne dojijo.
Additionally, it is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Še več, priporočljivo je, da ženske okužene z virusom HIV v nobenem primeru ne dojijo, da bi se tako preprečil prenos virusa HIV.
Hypersensitivity (see also section 4.4):
Preobčutljivost (glejte tudi poglavje 4. 4):
In clinical studies, approximately 5% of subjects receiving abacavir developed a hypersensitivity reaction.
V kliničnih študijah se je pri okoli 5% bolnikov, ki so jih zdravili z abakavirjem, razvila preobčutljivostna reakcija.
In clinical studies with abacavir 600 mg once daily the reported rate of hypersensitivity remained within the range recorded for abacavir 300 mg twice daily.
V kliničnih študijah z abakavirjem v odmerku 600 mg enkrat na dan je odstotek poročil o preobčutljivosti ostal v mejah, ki so bile opažene pri dajanju abakavirja v odmerku 300 mg dvakrat na dan.
Some of these hypersensitivity reactions were life-threatening and resulted in fatal outcome despite taking precautions.
Nekatere od teh preobčutljivostnih reakcij so bile življenjsko ogrožujoče in so se, kljub varnostnim ukrepom, končale s smrtjo.
This reaction is characterised by the appearance of symptoms indicating multi-organ/ body-system involvement.
Za to reakcijo je značilen pojav simptomov, ki nakazujejo prizadetost več telesnih organov/ sistemov.
Almost all patients developing hypersensitivity reactions will have fever and/ or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever.
8 Skoraj pri vseh bolnikih s preobčutljivostnimi reakcijami se, kot del sindroma, pojavi vročina in/ ali izpuščaj (navadno makulopapulozni in/ ali urtikarijski), pri nekaterih pa so se pojavile reakcije tudi brez izpuščaja ali vročine.
The signs and symptoms of this hypersensitivity reaction are listed below.
Znake in simptome takšne preobčutljivostne reakcije navajamo spodaj.
These have been identified either from clinical studies or post marketing surveillance.
Pojavili so se bodisi v kliničnih študijah ali v postmarketinških raziskavah.
Those reported in at least 10% of patients with a hypersensitivity reaction are in bold text.
Tisti o katerih so poročali pri vsaj 10% bolnikov s preobčutljivostno reakcijo, so napisani v krepkem tisku.
Skin Rash (usually maculopapular or urticarial)
Koža Izpuščaj (navadno makulopapulozni ali urtikarijski)
Nausea, vomiting, diarrhoea, abdominal pain, mouth ulceration
Slabost, bruhanje, driska, bolečine v trebuhu, ustne razjede
Dyspnoea, cough, sore throat, adult respiratory distress syndrome, respiratory failure
Dispneja, kašelj, bolečine v grlu, respiratorni distresni sindrom, odpoved dihanja
Fever, lethargy, malaise, oedema, lymphadenopathy,
Drugo Vročina, letargija, slabo počutje, edemi, limfadenopatija, hipotenzija, konjunktivitis, anafilaksa
Neurological/ Psychiatry
Živčevje/ psihiatrija
Liver/ pancreas
Jetra/ trebušna slinavka
Musculoskeletal
Mišičnoskeletni
Myalgia, rarely myolysis, arthralgia, elevated creatine phosphokinase
Mialgija, redko mioliza, artralgija, zvišane vrednosti kreatinske fosfokinaze
Urology
Urološki
Elevated creatinine, renal failure
Zvišane vrednosti kreatinina, ledvična odpoved
Rash (81% vs 67% respectively) and gastrointestinal manifestations (70% vs 54% respectively) were more frequently reported in children compared to adults.
Izpuščaj (81% v primerjavi s 67%) in gastrointestinalne manifestacije (70% v primerjavi s 54%) so se pogosteje pojavljale pri otrocih kakor pri odraslih.
This delay in diagnosis of hypersensitivity has resulted in Ziagen being continued or re-introduced, leading to more severe hypersensitivity reactions or death.
Ta zamuda pri diagnosticiranju preobčutljvosti je imela za posledico, da so bolniki še naprej jemali oziroma ponovno začeli jemati zdravilo Ziagen, kar je privedlo do še hujših preobčutljivostnih reakcij ali smrti.
Therefore, the diagnosis of hypersensitivity reaction should be carefully considered for patients presenting with symptoms of these diseases.
Zato je treba pri bolnikih, kjer se pokažejo takšni simptomi, pri postavljanju diagnoze dobro pretehtati, ali ne gre morda za preobčutljivostno reakcijo.
Symptoms usually appeared within the first six weeks (median time to onset 11 days) of initiation of treatment with abacavir, although these reactions may occur at any time during therapy.
Običajno se simptomi pojavijo v prvih šestih tednih (mediana časa pojava je 11 dni) od začetka zdravljenja z abakavirjem, čeprav se omenjene reakcije lahko pojavijo kadarkoli med zdravljenjem.
Close medical supervision is necessary during the first two months, with consultations every two weeks.
V prvih dveh mesecih je potreben natančen zdravstveni nadzor z rednimi posveti vsaka dva tedna.
It is likely that intermittent therapy may increase the risk of developing sensitisation and therefore occurrence of clinically significant hypersensitivity reactions.
Možno je, da zdravljenje s prekinitvami lahko poveča tveganje razvoja senzibilizacije in s tem pojavnost klinično pomembnih preobčutljivostnih reakcij.
Consequently, patients should be advised of the importance of taking Ziagen regularly.
Zato je treba bolnike seznaniti s tem, kako pomembno je redno jemanje zdravila Ziagen.
Restarting Ziagen following a hypersensitivity reaction results in a prompt return of symptoms within hours.
Pri ponovnem začetku zdravljenja z zdravilom Ziagen po prestani preobčutljivostni reakciji se simptomi pojavijo takoj, že v nekaj urah.
This recurrence of the hypersensitivity reaction was usually more severe than on initial presentation, and may include life-threatening hypotension and death.
Ponovitev preobčutljivostne reakcije je običajno resnejša kot ob prvem pojavu in lahko privede do življenjsko ogrožujoče hipotenzije in smrti.
Patients who develop this hypersensitivity reaction must discontinue Ziagen and must never be rechallenged with Ziagen, or any other medicinal product containing abacavir (i. e.
Bolniki, pri katerih se je razvila takšna preobčutljivostna reakcija, morajo prekiniti zdravljenje z zdravilom Ziagen in ne smejo biti zdravilu Ziagen ali drugemu zdravilu, ki vsebuje abakavir (npr.
Kivexa, Trizivir).
Kivexa, Trizivir), nikoli več izpostavljeni.
To avoid a delay in diagnosis and minimise the risk of a life-threatening hypersensitivity reaction, Ziagen must be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible (respiratory diseases, flu-like illness, gastroenteritis or reactions to other medications).
Kadar ne moremo izključiti preobčutljivosti in da bi se izognili zamudi pri diagnosticiranju in čimbolj zmanjšali tveganje za pojav življenjsko nevarne preobčutljivostne reakcije, moramo z dajanjem
Hypersensitivity reactions with rapid onset, including life-threatening reactions have occurred after restarting Ziagen in patients who had only one of the key symptoms of hypersensitivity (skin rash, fever, gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise) prior to stopping Ziagen.
Pri bolnikih, ki so imeli pred prenehanjem jemanja zdravila Ziagen samo enega od ključnih simptomov preobčutljivosti (kožni izpuščaj, vročino, gastrointestinalne, respiratorne ali konstitucionalne simptome, kakor sta letargija in slabo počutje), so po ponovnem začetku jemanja zdravila Ziagen naglo nastopile preobčutljivostne reakcije, vključno z življenjsko nevarnimi reakcijami.
The most common isolated symptom of a hypersensitivity reaction was a skin rash.
Najpogosteje izoliran simptom preobčutljivostne reakcije je bil kožni izpuščaj.
Moreover, on very rare occasions hypersensitivity reactions have been reported in patients who have restarted therapy and who had no preceding symptoms of a hypersensitivity reaction.
Preobčutljivostne reakcije so bile v redkih primerih opažene tudi pri bolnikih, ki so znova začeli z zdravljenjem, a pred tem niso imeli nobenih simptomov preobčutljivostne reakcije.
In both cases, if a decision is made to restart Ziagen this must be done in a setting where medical assistance is readily available.
V obeh primerih velja, da če se odločite za ponovno jemanje zdravila Ziagen, storite to v okolju, kjer bo na razpolago takojšnja medicinska pomoč.
Each patient must be warned about this hypersensitivity reaction to abacavir.
Vsak bolnik mora biti opozorjen na preobčutljivostne reakcije zaradi abakavirja.
For many of the other adverse reactions reported, it is unclear whether they are related to Ziagen, to the wide range of medicinal products used in the management of HIV infection or as a result of the disease process.
Za številne druge neželene učinke, o katerih so poročali, ni ugotovljeno, ali so povezani z zdravilom Ziagen ali z velikim številom zdravil, ki se uporabljajo za zdravljenje okužbe s HIV, ali pa so se pojavili kot posledica samega bolezenskega procesa.
9 Many of those listed below occur commonly (nausea, vomiting, diarrhoea, fever, lethargy, rash) in patients with abacavir hypersensitivity.
Mnogi od spodaj navedenih (slabost, bruhanje, driska, vročina, letargija, izpuščaj) se pogosto pojavijo pri bolnikih preobčutljivih za abakavir.
Therefore, patients with any of these symptoms should be carefully evaluated for the presence of this hypersensitivity reaction.
Zato moramo bolnike z katerimkoli od teh simptomov skrbno opazovati, če se pojavi preobčutljivostna reakcija.
If Ziagen has been discontinued in patients due to experiencing any one of these symptoms and a decision is made to restart a medicinal product containing abacavir, this must be done in a setting where medical assistance is readily available (see section 4.4.).
Če je bolnik prenehal z jemanjem zdravila Ziagen, zdravila, ki vsebuje abakavir, zaradi pojava enega od naštetih simptomov in mora ponovno pričeti z jemanjem, naj stori to v prostorih, ki omogočajo takojšnjo zdravniško pomoč (glejte poglavje 4. 4.).
Very rarely cases of erythema multiforme, Stevens Johnson syndrome or toxic epidermal necrolysis have been reported where abacavir hypersensitivity could not be ruled out.
Poročali so o zelo redkih primerih multiformnega eritema, Stevens Johnson- ovega sindroma in toksični epidermalni nekrolizi, kjer preobčutljivosti na abakavir niso mogli izključiti.
In such cases medicinal products containing abacavir should be permanently discontinued.
V takih primerih je treba z jemanjem zdravila, ki vsebuje abakavir popolnoma prenehati.
The following convention has been used for their classification: very common (> 1/ 10), common (> 1/ 100 ,< 1/10), uncommon (> 1/ 1,000 ,< 1/100), rare (> 1/ 10,000, < 1/ 1,000) very rare (< 1/ 10,000).
Klasificirani so bili na naslednji način: zelo pogosti (> 1/ 10), pogosti (> 1/ 100, < 1/ 10), občasni (> 1/ 1. 000, < 1/ 100), redki (> 1/ 10. 000, < 1/ 1. 000), zelo redki (< 1/ 10. 000).
Metabolism and nutrition disorders Common: anorexia
Pogosti: anoreksija
Gastrointestinal disorders Common: nausea, vomiting, diarrhoea Rare: pancreatitis
Bolezni prebavil Pogosti: slabost, bruhanje, driska Redki: pankreatitis
Skin and subcutaneous tissue disorders Common: rash (without systemic symptoms) Very rare: erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis
Bolezni kože in podkožja Pogosti: izpuščaj (brez sistemskih simptomov) Zelo redki: multiformni eritem, Stevens- Johnsonov sindrom in toksična epidermalna nekroliza
General disorders and administration site conditions Common: fever, lethargy, fatigue
Splošne težave in spremembe na mestu aplikacije Pogosti: vročina, letargija, utrujenost.
Cases of lactic acidosis, sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues (see section 4.4).
Pri uporabi nukleozidnih analogov so poročali o primerih laktacidoze, včasih smrtne, običajno povezane z hudo hepatomegalijo in jetrno steatozo (glejte poglavje 4. 4).
Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump).
Kombinirano protiretrovirusno zdravljenje so pri bolnikih s HIV povezali s prerazporeditvijo telesnega maščevja (lipodistrofija), vključno z izgubo periferne in podkožne maščobe, povečanjem intraabdominalne in visceralne maščobe, povečanjem prsi in nalaganjem maščobe v dorsocervikalnem predelu (bivolja grba).
Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
10 Sočasno zdravljenje z več protiretrovirusnimi zdravili je povezano z presnovnimi motnjami, kot so hipertrigliceridemija, hiperholesterolemija, inzulinska rezistenca, hiperglikemija in povišana koncentracija laktata v krvi (glejte poglavje 4. 4).
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART) an inflammatory reaction to asymptomatic or residual opportunistic infections may arise (see section 4.4).
Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART - "combination antiretroviral therapy") nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične okužbe (glejte poglavje 4. 4).
Laboratory abnormalities In controlled clinical studies laboratory abnormalities related to Ziagen treatment were uncommon, with no differences in incidence observed between Ziagen treated patients and the control arms.
V nadzorovanih kliničnih študijah so le redko opazili laboratorijske nenormalnosti, povezane z zdravilom Ziagen, pri čemer v incidenci med bolniki, zdravljenimi z zdravilom Ziagen, in kontrolnimi skupinami niso opazili razlik.
10 4.9 Overdose
4. 9 Preveliko odmerjanje
No unexpected adverse reactions were reported.
Poročil o nepričakovanih neželenih učinkih ni bilo.
If overdose occurs the patient should be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary.
V primeru prevelikega odmerjanja je treba bolnika spremljati in nadzorovati zaradi toksičnosti (glejte poglavje 4. 8) in izvajati ustrezno standardno podporno zdravljenje.
Pharmacotherapeutic group: nucleoside reverse transcriptase inhibitors, ATC Code:
Farmakoterapevtska skupina: zaviralci nukleozidne reverzne transkriptaze, oznaka ATC:
It is a potent selective inhibitor of HIV-1 and HIV-2.
Je močan selektiven zaviralec HIV- 1 in HIV- 2.
Abacavir is metabolised intracellularly to the active moiety, carbovir 5’ - triphosphate (TP).
Abakavir se v celicah presnavlja v aktivno obliko, karbovir 5 '- trifosfat (TP).
Abacavir shows synergy in vitro in combination with nevirapine and zidovudine.
Abakavir je in vitro v kombinaciji z nevirapinom in zidovudinom pokazal sinergističen učinek.
It has been shown to be additive in combination with didanosine, lamivudine and stavudine.
Izkazalo se je, da ima v kombinaciji z didanozinom, lamivudinom in stavudinom aditiven učinek.
Abacavir-resistant isolates of HIV-1 have been selected in vitro and are associated with specific genotypic changes in the reverse transcriptase (RT) codon region (codons M184V, K65R, L74V and Y115F).
Izolati HIV– 1, rezistentni na abakavir, so bili izolirani in vitro in so povezani s specifičnimi genotipskimi spremembami v kodonskem območju (kodoni M184V, K65R, L74V in Y115F) reverzne transkriptaze (RT).
In vivo resistance (Therapy naïve patients) Isolates from most patients experiencing virological failure with a regimen containing abacavir in pivotal clinical trials showed either no NRTI-related changes from baseline (45%) or only M184V or M184I selection (45%).
V ključnih kliničnih preskušanjih pri izolatih večine bolnikov z virusnim neodzivom pri zdravljenju z režimom, ki je vseboval abakavir, bodisi niso odkrili z NRTI- ji povezanih sprememb od izhodišča (45%) ali pa so odkrili le selekcijo M184V ali M184I (45%).